References
- Mortenson L. E. Audit indicates half of current chemotherapy uses lack FDA approval. J Cancer Program Mgmt 1988; 3(1)21–25
- Mortenson L. E. Audit indicates many uses of combination therapy are unlabeled. J Cancer Program Mgmt 1988; 3(1)33
- Yarbro W., Mortenson L. E. The need for DRG 471 — protection for clinical research. J Am Med Assoc 1985; 253(5)684–685
- Davis C. The impact of prospective payment on clinical research progress. J Am Med Assoc 1985; 253(5)686–687